{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-086246","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2025-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.687431+00:00","generated_at":"2026-05-19T08:46:28.794484+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Acrivon stockholders elect three Class III directors and ratify PwC as auditor","bullets":["Quorum of 29,659,010 shares (94.59%) present at 2025 annual meeting on June 13.","Peter Blume-Jensen (26,612,623 for), Derek DiRocco (24,606,548), Santhosh Palani (26,246,868) elected as Class III directors.","Ratification of PricewaterhouseCoopers LLP as auditor for FY2025: 29,653,924 for, 3,673 against, 1,413 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-086246","json":"https://secwatch.observer/filing/0000950170-25-086246.json","markdown":"https://secwatch.observer/filing/0000950170-25-086246.md","text":"https://secwatch.observer/filing/0000950170-25-086246.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025086246/0000950170-25-086246-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025086246/acrv-20250613.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T08:46:28.794484+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}